forecast glp-1 prescriptions growth 2025 Receptor Agonist Market Analysis GLP-1 Receptor Agonist Market Size

8.5 Geriatric Use In the liraglutide injection treatment arms of the glycemic control trials, a total of 832 (19.3%) of the patients were 65 to 74 years of age and 145 (3.4%) were 75 years of age and over [see Clinical Studies (14.1)]

Patients with type 2 diabetes who are overweight may find Semaglutide GLP-1 to be a useful therapy choice because of its ability to help patients lose weight

Whilst synthetic GLP-1 receptor agonists such as semaglutide have gained prominence for diabetes and weight management, many people seek evidence-based strategies to enhance their body's own GLP-1 production

Incretin-based therapies for type 2 diabetes mellitus

For comparison, fewer than half of those on placebo reported similar symptoms